T Cells Engineered with CAR Targeting CD19 in Patients with Relapsed/Refractory ALL


T Cells Engineered with CAR Targeting CD19 in Patients with Relapsed/Refractory ALL
Slides from a presentation at ASH 2013 and transcribed comments from recent interviews with Hagop M Kantarjian, MD (1/29/14) and David L Porter, MD (3/3/14)
Grupp SA et al. T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) produce significant in vivo proliferation, complete responses and long-term persistence without GVHD in children and adults with relapsed, refractory ALL. Proc ASH 2013;Abstract 67.

Dr Kantarjian is Chairman and Professor in the Leukemia Department at The University of Texas MD Anderson Cancer Center in Houston, Texas.

Dr Porter is Jodi Fisher Horowitz Professor of Leukemia Care Excellence and Director of Blood and Marrow Transplantation at the University of Pennsylvania Health System's Abramson Cancer Center in Philadelphia, Pennsylvania.